Cefadroxil
Brand names: Cefadroxil
At a glance
- Medicare prescriptions, 2024
- 373,380
- Medicare drug cost
- $4.6M
- Average cost per prescription
- $12.40
- Clinicians who prescribed it
- 11,180
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Cefadroxil is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli, P. mirabilis, and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available. Note: Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil and other antibacterial drugs, cefadroxil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemology and susceptibility patterns may…
From the FDA-approved prescribing information (label dated April 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Physician Assistants 20.8%
- Orthopedic Surgery 12.7%
- Family Medicine 10.1%
- Infectious Disease 9.3%
- Internal Medicine 8.5%
- Nurse Practitioners 8.4%
- Emergency Medicine 4.3%
- Podiatrists 3.8%
- Dermatology 3.5%
- Joint Replacement Surgery 2.8%
- Mohs Surgery 2.5%
- Urology 2.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 117% from 2019 to 2024.
Biggest change by state since 2019
- California +274%
- Florida +198%
- Minnesota +198%
- North Carolina +153%
- Pennsylvania +119%
- Puerto Rico (smallest change) −21%
- New Jersey (smallest change) +34%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Preferred Pharmaceuticals Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white capsule, 21 mm | C 97 |
Preferred Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white capsule, 22 mm | LU F11 |
Proficient Rx LP
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white capsule, 22 mm | LU F11 |
Redpharm Drug
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white capsule, 21 mm | C 97 |
Remedyrepack Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white capsule, 22 mm | LU F11 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.